Emerging therapeutic potential of regulatory T (Treg) cells for rheumatoid arthritis : New insights and challenges
Copyright © 2022 Elsevier B.V. All rights reserved..
Rheumatoid arthritis (RA) is an autoimmune-related disorder characterized by chronic inflammation. Although the etiopathogenesis of RA still remains to be clarified, it is supposed that the breakdown of immune self-tolerance may contribute to the development of RA. Thus, restoring of immune tolerance at the site of inflammation is the ultimate goal of RA treatment. Regulatory T cells (Treg cells) are the main suppressive cells that maintain tolerance and inhibit immunity against auto-antigen. Of note, recent studies demonstrated the efficacy of adoptive transfer of Treg cells in the modulation of the unwanted immune response, which makes them an ideal candidate to maintain immune homeostasis and restore antigen-specific tolerance in the case of RA and other autoimmune diseases. This review intends to submit recent finding of Treg cells-based therapies in RA with a focus on strategies applied to improve the therapeutic value of Treg cells to restore immune tolerance.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
International immunopharmacology - 108(2022) vom: 15. Juli, Seite 108858 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rezaei Kahmini, Fatemeh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens |
|---|
| Anmerkungen: |
Date Completed 21.06.2022 Date Revised 21.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.intimp.2022.108858 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341196983 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341196983 | ||
| 003 | DE-627 | ||
| 005 | 20231226011226.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.intimp.2022.108858 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1137.xml |
| 035 | |a (DE-627)NLM341196983 | ||
| 035 | |a (NLM)35597122 | ||
| 035 | |a (PII)S1567-5769(22)00342-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rezaei Kahmini, Fatemeh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging therapeutic potential of regulatory T (Treg) cells for rheumatoid arthritis |b New insights and challenges |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2022 | ||
| 500 | |a Date Revised 21.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a Rheumatoid arthritis (RA) is an autoimmune-related disorder characterized by chronic inflammation. Although the etiopathogenesis of RA still remains to be clarified, it is supposed that the breakdown of immune self-tolerance may contribute to the development of RA. Thus, restoring of immune tolerance at the site of inflammation is the ultimate goal of RA treatment. Regulatory T cells (Treg cells) are the main suppressive cells that maintain tolerance and inhibit immunity against auto-antigen. Of note, recent studies demonstrated the efficacy of adoptive transfer of Treg cells in the modulation of the unwanted immune response, which makes them an ideal candidate to maintain immune homeostasis and restore antigen-specific tolerance in the case of RA and other autoimmune diseases. This review intends to submit recent finding of Treg cells-based therapies in RA with a focus on strategies applied to improve the therapeutic value of Treg cells to restore immune tolerance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Autoimmune diseases | |
| 650 | 4 | |a Immune tolerance | |
| 650 | 4 | |a Regulatory T-cell | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Treg cells-based therapy | |
| 650 | 7 | |a Antigens |2 NLM | |
| 700 | 1 | |a Shahgaldi, Shahab |e verfasserin |4 aut | |
| 700 | 1 | |a Azimi, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Mansourabadi, Amir Hossein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International immunopharmacology |d 2001 |g 108(2022) vom: 15. Juli, Seite 108858 |w (DE-627)NLM112639542 |x 1878-1705 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2022 |g day:15 |g month:07 |g pages:108858 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.intimp.2022.108858 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2022 |b 15 |c 07 |h 108858 | ||